CRMD
CorMedix Inc
7.90$
+1.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -100.0% | – | +1,321.1% | +172.4% | +25.2% | +1.7% | +162.4% | +23.3% | -0.9% | -20.0% | – | |
| – | +3.2% | +1,429.8% | -37.7% | +34.7% | +71.2% | +35.8% | +16.6% | +501.1% | +90.3% | +4.7% | +11.2% | – | |
| – | – | – | – | +3,534.9% | +178.9% | +24.8% | +1.0% | +145.8% | +15.3% | -2.0% | -26.6% | – | |
| – | -14.1% | -63.4% | -22.3% | +11.7% | +137.5% | +84.9% | -23.5% | +108.7% | +68.7% | -16.1% | -7.3% | – | |
| – | +39.4% | +66.9% | -13.2% | -12.9% | +8.0% | +36.4% | -2.0% | +167.8% | -7.4% | -7.9% | -30.5% | – | |
| – | +49.9% | +1.7% | -1.8% | -9.9% | +21.6% | +1.5% | +5.6% | +127.7% | +15.4% | -13.9% | -17.5% | – | |
| – | – | – | – | – | – | +55.6% | -2.9% | +162.7% | +15.2% | +7.7% | -32.6% | – | |
| – | -50.0% | +50.0% | -33.3% | +52.6% | +0.0% | +0.0% | -33.3% | +14,114.4% | +91.6% | – | – | – | |
| – | – | – | – | – | – | +53.3% | -1.4% | +158.4% | +7.4% | -1.4% | -30.4% | – | |
| – | -100.0% | -46,492,433.3% | – | -5,735,800.0% | – | – | – | -10,835.6% | – | -59.8% | -25.2% | – | |
| – | – | – | – | – | – | +53.3% | -4.0% | +447.5% | -87.1% | +175.3% | -32.7% | – | |
| – | – | – | – | – | – | +53.0% | -1.4% | +179.3% | +19.9% | -3.7% | -13.3% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.